↓ Skip to main content

Diagnostic utility of DREAM gene mRNA levels in thyroid tumours

Overview of attention for article published in Archives of Endocrinology and Metabolism, March 2018
Altmetric Badge

Readers on

mendeley
10 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Diagnostic utility of DREAM gene mRNA levels in thyroid tumours
Published in
Archives of Endocrinology and Metabolism, March 2018
DOI 10.20945/2359-3997000000028
Pubmed ID
Authors

Batista, Fernando A., Marcello, Marjory A., Martins, Mariana B., Peres, Karina C., Cardoso, Ulieme O., Silva, Aline C. D. N., Bufalo, Natassia E., Soares, Fernando A., Silva, Márcio J. da, Assumpção, Lígia V., Ward, Laura S.

Abstract

The transcriptional repressor DREAM is involved in thyroid-specific gene expression, thyroid enlargement and nodular development, but its clinical utility is still uncertain. In this study we aimed to investigate whether DREAM mRNA levels differ in different thyroid tumors and how this possible difference would allow the use of DREAM gene expression as molecular marker for diagnostic and/or prognosis purpose. We quantified DREAM gene mRNA levels and investigated its mutational status, relating its expression and genetic changes to diagnostic and prognostic features of 200 thyroid tumors, being 101 malignant [99 papillary thyroid carcinomas (PTC) and 2 anaplastic thyroid carcinomas] and 99 benign thyroid lesions [49 goiter and 50 follicular adenomas (FA)]. Levels of mRNA of DREAM gene were higher in benign (0.7909 ± 0.6274 AU) than in malignant (0.3373 ± 0.6274 AU) thyroid lesions (p < 0.0001). DREAM gene expression was able to identify malignancy with 66.7% sensitivity, 85.4% specificity, 84.2% positive predictive value (PPV), 68.7% negative predictive value (NPV), and 75.3% accuracy. DREAM mRNA levels were also useful distinguishing the follicular lesions FA and FVPTC with 70.2% sensitivity, 73.5% specificity, 78.5% PPV, 64.1% NPV, and 71.6% accuracy. However, DREAM gene expression was neither associated with clinical features of tumor aggressiveness, nor with recurrence or survival. Six different genetic changes in non-coding regions of DREAM gene were also found, not related to DREAM gene expression or tumor features. We suggest that DREAM gene expression may help diagnose thyroid nodules, identifying malignancy and characterizing follicular-patterned thyroid lesions; however, it is not useful as a prognostic marker.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 10 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 2 20%
Student > Bachelor 1 10%
Lecturer 1 10%
Other 1 10%
Professor 1 10%
Other 3 30%
Unknown 1 10%
Readers by discipline Count As %
Medicine and Dentistry 5 50%
Biochemistry, Genetics and Molecular Biology 2 20%
Pharmacology, Toxicology and Pharmaceutical Science 1 10%
Unknown 2 20%